# N-Acetyl Cysteine as a promising therapeutic approach in ovarian cancer: potential and perspectives

## TL;DR

This paper reviews how N-acetylcysteine (NAC) may help treat ovarian cancer by reducing toxicity and improving chemotherapy response.

## Contribution

The paper highlights NAC's potential as a chemo-protectant and explores mechanisms to overcome drug resistance in ovarian cancer.

## Key findings

- NAC reduces oxidative stress and may enhance chemotherapy response in ovarian cancer.
- NAC shows promise in targeting the Mirk/dyrk1B kinase pathway to overcome chemo resistance.
- NAC's effectiveness depends on tumor subtype, redox context, and treatment timing.

## Abstract

Ovarian cancer is the seventh most common cancer in women and the eighth most common cause of cancer death worldwide. It is an aggressive disease with five-year survival rates below 45% and many patients relapse within 2 years. Further treatments become more intense, resulting in chemotherapy drug resistance and increased toxicity. This has created the need to develop new therapeutic strategies to improve the quality of life and treatment options for ovarian cancer patients. Studies have reported the role of cysteine in ovarian cancer, primarily as a precursor of glutathione (GSH), contributing to the endogenous antioxidant mechanism. The membrane-permeable cysteine precursor N-acetylcysteine (NAC) can enhance the intracellular cysteine pool and thus results in decreased oxidative stress. This characteristic provides NAC with a rationale as a potentially effective chemo-protectant in ovarian cancer treatment. In this review, we summarize the effects of NAC supplementation in ovarian cancer from recent preclinical studies. The role of NAC in chemotherapy response, and mechanisms to overcome chemo resistance in ovarian cancer (including targeting the Mirk/dyrk1B kinase pathway) are also explored. While NAC holds therapeutic promise in alleviating treatment-associated toxicities, its application in ovarian cancer requires careful consideration based on tumour subtype, redox context, and treatment timing. Future research incorporating subtype-specific models and clinical trials will be essential to delineate the precise role of NAC and optimize its integration into ovarian cancer treatment regimens.